已核实 DOI 相关产品: 0

LC-MS/MS method for quantification of dupilumab in human serum using Protein G enrichment

Journal 2026 · IF 3.4 · 发表于 2026 年 10 月 2 日
作者: Kun Yang,Jianhua Wu,Chengming Yang,Liang Liu
阅读全文 在 PubMed 查看

摘要

A Protein G magnetic bead-based LC-MS/MS method was developed for dupilumab quantification in human serum. • The surrogate peptide SGQSPQLLIYLGSNR enabled sensitive and specific targeted detection (LLOQ 1.00 µg/mL). • Excellent linearity, precision and accuracy were achieved across a wide dynamic range (1.00–400 µg/mL). • Considerable interpatient variability was observed in clinical trough samples. Dupilumab, a monoclonal antibody targeting IL-4Rα, is used for the treatment of type 2 inflammatory diseases. Recent studies have revealed a nonlinear relationship between its serum concentration and clinical response, particularly a “biological tipping point” during dose interval prolongation, highlighting the need for individualized therapeutic drug monitoring (TDM). In this study, a robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for dupilumab quantification in human serum was developed and validated. Specifically, dupilumab was enriched from 50 µL serum using Protein G magnetic beads, followed by denaturation, reduction, alkylation, and tryptic digestion. A surrogate peptide SGQSPQLLIYLGSNR was selected for quantification, and its stable isotope-labeled (SIL) analog served as an internal standard. Separation was performed on an Acquity UPLC BEH C 8 column (50 mm × 2.1 mm, 1.7 µm) with detection using positive electrospray ionization in multiple reaction monitoring (MRM) mode. Excellent linearity was achieved from 1.00 to 400 µg/mL (r² > 0.99), with a lower limit of quantification of 1.00 µg/mL. Intra- and inter-run precision (%CV) and accuracy (%Bias) were within 9.27%. The validated method was successfully applied to analyze clinical serum samples. The established LC-MS/MS method provides a reliable alternative to immunoassays, with a wide dynamic range suitable for TDM and personalized dose interval adjustments in patients receiving dupilumab. Download: Download high-res image (93KB) Download: Download full-size image